Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia

Increasing evidence suggests an interaction of oxidative stress and the formation of advanced glycation end products (AGE) in the onset and progression of Alzheimer's disease. We studied levels of pentosidine and N(epsilon)-(carboxymethyl)-lysine (CML) in serum and cerebrospinal fluid (CSF) of...

Full description

Saved in:
Bibliographic Details
Published in:Neurobiology of aging 2003-03, Vol.24 (2), p.333-338
Main Authors: Bär, K J, Franke, S, Wenda, B, Müller, S, Kientsch-Engel, R, Stein, G, Sauer, H
Format: Article
Language:English
Subjects:
Aged
Aging - metabolism
Alzheimer Disease - metabolism
Analysis of Variance
Arginine - analogs & derivatives
Arginine - blood
Dementia, Vascular - metabolism
Female
Glycation End Products, Advanced - blood
Humans
Lysine - analogs & derivatives
Lysine - blood
Male
Middle Aged
Oxidative Stress
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increasing evidence suggests an interaction of oxidative stress and the formation of advanced glycation end products (AGE) in the onset and progression of Alzheimer's disease. We studied levels of pentosidine and N(epsilon)-(carboxymethyl)-lysine (CML) in serum and cerebrospinal fluid (CSF) of 15 patients with probable Alzheimer's disease (AD), 20 patients with vascular dementia (VD), and 31 control subjects (14 matched for age, and 17 younger patients). AGE protein concentrations in CSF did not differ within controls when divided into two subgroups by age. We found significantly elevated levels of CML in CSF of AD patients and of pentosidine in CSF of patients suffering from vascular dementia when compared to controls. The concentrations of pentosidine and CML in serum apparently did not relate directly to CSF values, suggesting influence of extra-cerebral factors in serum samples. It is concluded that AGE proteins are differentially affected in these types of dementia, depending on the specific neuropathology. Furthermore, measurements of AGE products in vivo should rely on CSF rather than blood samples.
ISSN:0197-4580
DOI:10.1016/S0197-4580(02)00086-6